Analogs of the novel phytohormone, strigolactone, trigger apoptosis and synergize with PARP inhibitors by inducing DNA damage and inhibiting DNA repair
暂无分享,去创建一个
Y. Pommier | R. Yarden | C. Albanese | C. Prandi | K. Agama | H. Koltai | Jamie P Schlarbaum | Jeannine R. LaRocque | L. Tricoli | Yaron Dayani | E. Artuso | Michael P. Croglio | Yu Chen | Jefferson M. Haake | Colin P. Ryan | Victor S. Wang | Jennifer Lapier | Emma Artuso
[1] H. Koltai. Cellular events of strigolactone signalling and their crosstalk with auxin in roots. , 2015, Journal of experimental botany.
[2] R. Yarden,et al. Strigolactone analogs act as new anti-cancer agents in inhibition of breast cancer in xenograft model , 2015, Cancer biology & therapy.
[3] M. Kumar,et al. Strigolactone signaling in root development and phosphate starvation , 2015, Plant signaling & behavior.
[4] Ilya Shmulevich,et al. Augmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancers. , 2015, Journal of the National Cancer Institute.
[5] M. Kastan,et al. Repair versus Checkpoint Functions of BRCA1 Are Differentially Regulated by Site of Chromatin Binding. , 2015, Cancer research.
[6] O. Leyser,et al. Strigolactone signalling: standing on the shoulders of DWARFs. , 2014, Current opinion in plant biology.
[7] H. Koltai. Receptors, repressors, PINs: a playground for strigolactone signaling. , 2014, Trends in plant science.
[8] Chin-Lee Wu,et al. The induction of the p53 tumor suppressor protein bridges the apoptotic and autophagic signaling pathways to regulate cell death in prostate cancer cells , 2014, Oncotarget.
[9] Hans Clevers,et al. Organoid Cultures Derived from Patients with Advanced Prostate Cancer , 2014, Cell.
[10] S. Baylin,et al. Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance. , 2014, Molecular cell.
[11] D. Reglodi,et al. PACAP27 is Protective Against Tat-Induced Neurotoxicity , 2014, Journal of Molecular Neuroscience.
[12] R. Yarden,et al. Strigolactone analogues induce apoptosis through activation of p38 and the stress response pathway in cancer cell lines and in conditionally reprogramed primary prostate cancer cells. , 2014, Oncotarget.
[13] Matthias Dobbelstein,et al. Targeting tumour-supportive cellular machineries in anticancer drug development , 2014, Nature Reviews Drug Discovery.
[14] Michal Zimmermann,et al. 53BP1: pro choice in DNA repair. , 2014, Trends in cell biology.
[15] C. Albanese,et al. Radiation induces diffusible feeder cell factor(s) that cooperate with ROCK inhibitor to conditionally reprogram and immortalize epithelial cells. , 2013, The American journal of pathology.
[16] R. Yarden,et al. BRCA1 targets G2/M cell cycle proteins for ubiquitination and proteasomal degradation , 2013, Oncogene.
[17] R. Livingston,et al. Differential chemotherapeutic sensitivity for breast tumors with "BRCAness": a review. , 2013, The oncologist.
[18] Phang-lang Chen,et al. A novel small molecule RAD51 inactivator overcomes imatinib-resistance in chronic myeloid leukaemia , 2013, EMBO molecular medicine.
[19] M. Papa,et al. BRCA1-dependent Chk1 phosphorylation triggers partial chromatin disassociation of phosphorylated Chk1 and facilitates S-phase cell cycle arrest. , 2012, The international journal of biochemistry & cell biology.
[20] Peter Bouwman,et al. The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance , 2012, Nature Reviews Cancer.
[21] T. Taniguchi,et al. MiR-96 downregulates REV1 and RAD51 to promote cellular sensitivity to cisplatin and PARP inhibition. , 2012, Cancer research.
[22] H. Joenje,et al. Diagnosis of Fanconi Anemia: Chromosomal Breakage Analysis , 2012, Anemia.
[23] Chris Albanese,et al. ROCK inhibitor and feeder cells induce the conditional reprogramming of epithelial cells. , 2012, The American journal of pathology.
[24] A. Ashworth,et al. The DNA damage response and cancer therapy , 2012, Nature.
[25] L. Symington,et al. Double-strand break end resection and repair pathway choice. , 2011, Annual review of genetics.
[26] B. Kaina,et al. Rad51 and BRCA2 - New Molecular Targets for Sensitizing Glioma Cells to Alkylating Anticancer Drugs , 2011, PloS one.
[27] Yun-Wei Lin,et al. Down-Regulation of Rad51 Expression Overcomes Drug Resistance to Gemcitabine in Human Non–Small-Cell Lung Cancer Cells , 2010, Journal of Pharmacology and Experimental Therapeutics.
[28] E. Alli,et al. Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatin. , 2010, Cancer research.
[29] J. Settleman,et al. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer , 2010, Oncogene.
[30] Y. Kapulnik,et al. Strigolactones are positive regulators of light-harvesting genes in tomato , 2010, Journal of experimental botany.
[31] Yan Geng,et al. Role of DNA in condensation and combinative self-assembly. , 2010, Chemical communications.
[32] Yves Pommier,et al. The complexity of phosphorylated H2AX foci formation and DNA repair assembly at DNA double-strand breaks , 2010, Cell cycle.
[33] T. Chou. Drug combination studies and their synergy quantification using the Chou-Talalay method. , 2010, Cancer research.
[34] A. Ashworth,et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. , 2009, The New England journal of medicine.
[35] D. Schild,et al. Overexpression of RAD51 suppresses recombination defects: a possible mechanism to reverse genomic instability , 2009, Nucleic Acids Research.
[36] Y. Pommier,et al. DNA cleavage assay for the identification of topoisomerase I inhibitors , 2008, Nature Protocols.
[37] H. Klein,et al. The consequences of Rad51 overexpression for normal and tumor cells. , 2008, DNA repair.
[38] F. Alt,et al. Distinct roles of chromatin-associated proteins MDC1 and 53BP1 in mammalian double-strand break repair. , 2007, Molecular cell.
[39] Dihua Yu,et al. Rad51 overexpression contributes to chemoresistance in human soft tissue sarcoma cells: a role for p53/activator protein 2 transcriptional regulation , 2007, Molecular Cancer Therapeutics.
[40] Alan Ashworth,et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. , 2006, Cancer research.
[41] F. Couch,et al. Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. , 2006, Molecular cell.
[42] Jiri Bartek,et al. Spatial organization of the mammalian genome surveillance machinery in response to DNA strand breaks , 2006, The Journal of cell biology.
[43] Alan Ashworth,et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.
[44] Thomas Helleday,et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase , 2005, Nature.
[45] Jiri Bartek,et al. Chk1 and Chk2 kinases in checkpoint control and cancer. , 2003, Cancer cell.
[46] Lawrence C. Brody,et al. BRCA1 regulates the G2/M checkpoint by activating Chk1 kinase upon DNA damage , 2002, Nature Genetics.
[47] Ashok R Venkitaraman,et al. Cancer Susceptibility and the Functions of BRCA1 and BRCA2 , 2002, Cell.
[48] B. Modan,et al. Effect of BRCA mutations on the length of survival in epithelial ovarian tumors. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[49] Jeremy M. Stark,et al. Double-strand breaks and tumorigenesis. , 2001, Trends in cell biology.
[50] H. Stürzbecher,et al. Over‐expression of wild‐type Rad51 correlates with histological grading of invasive ductal breast cancer , 2000, International journal of cancer.
[51] V. Yamazaki,et al. A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage , 2000, Current Biology.
[52] H. Stürzbecher,et al. DNA repair and recombination factor Rad51 is over-expressed in human pancreatic adenocarcinoma , 2000, Oncogene.
[53] Y. Pommier,et al. Induction of topoisomerase I cleavage complexes by 1-beta -D-arabinofuranosylcytosine (ara-C) in vitro and in ara-C-treated cells. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[54] Y. Pommier,et al. Induction of Reversible Complexes between Eukaryotic DNA Topoisomerase I and DNA-containing Oxidative Base Damages , 1999, The Journal of Biological Chemistry.
[55] P. Baumann,et al. Role of the human RAD51 protein in homologous recombination and double-stranded-break repair. , 1998, Trends in biochemical sciences.
[56] S. Vispé,et al. Overexpression of Rad51 protein stimulates homologous recombination and increases resistance of mammalian cells to ionizing radiation. , 1998, Nucleic acids research.
[57] M. Jasin,et al. Homology-directed repair is a major double-strand break repair pathway in mammalian cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[58] A. Ashworth,et al. Tumorigenesis and a DNA repair defect in mice with a truncating Brca2 mutation , 1997, Nature Genetics.
[59] K. Khanna,et al. Targeting homologous recombination, new pre-clinical and clinical therapeutic combinations inhibiting RAD51. , 2015, Cancer treatment reviews.
[60] C. Beveridge,et al. Diverse roles of strigolactones in plant development. , 2013, Molecular plant.
[61] A. McCullough. ROCK Inhibitor and Feeder Cells Induce the Conditional Reprogramming of Epithelial Cells , 2013 .
[62] J. Stark,et al. I-SceI-based assays to examine distinct repair outcomes of mammalian chromosomal double strand breaks. , 2012, Methods in molecular biology.
[63] F. Zunino,et al. In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems , 1998, Cancer Chemotherapy and Pharmacology.
[64] D. Kern,et al. In vitro pharmacodynamics of 1-beta-D-arabinofuranosylcytosine: synergy of antitumor activity with cis-diamminedichloroplatinum(II). , 1988, Cancer research.